It is herein discussed what should be measured as predictors of atherosclerosis, to increase the predictive power of coronary risk evaluation in clinical practice. Several novel risk factors have been proposed as potential criteria for improved detection of subclinical atherosclerosis. Clinical interest has focused on emerging lipid parameters such as lipoprotein (a) [Lp(a)], apolipoproteins (apo), inflammatory markers such as high sensitive C-reactive protein (hs-CRP) and fibrinogen, and nutritional markers associated with premature atherothrombosis, such as total plasma homocycteine. It has been uncertain whether screening for any of these novel biomarkers substantially improves risk prediction over that associated with standard lipid screening alone. Plasma apoB and apoAI have been reported to be stronger predictors of coronary artery disease (CAD) than plasma low-density lipoprotein (LDL-cholesterol) and high-density lipoprotein (HDL-C). High plasma levels of Lp(a) are a risk factor for atherosclerotic vascular diseases in subjects with high plasma LDL-C levels and multiple coronary risk factors. Metabolic syndrome (MS) has been recognized recently as a predictor of CAD. As a result, it should be elucidated whether MS must be involved in the coronary risk evaluation score because all components of MS are involved in the score. A high plasma level of hs-CRP is an important predictor of atherosclerotic diseases. Many studies show that hs-CRP testing combined with lipid screening provide an improved method of detecting subclinical atherosclerosis.Whether it is essential to measure the plasma levels of atherosclerosis surrogate markers in clinical practice remains to be elucidated. It is concluded that plasma levels of apoproteins, homocysteine, Lp(a), hs-CRP and fibrinogen in addition to those of lipids should be measured as predictors of atherosclerosis in clinical practice. We need to establish a new atherosclerosis risk evaluation scoring system involving the above factors, based on large-scale, prospective studies, to prevent atherosclerotic vascular diseases. Levels of these prameters should be routinely measured in clinical practice in future to establish a new atherosclerosis risk evaluation scoring system in India.
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Biomarkers for Diagnosis and Prognostication of Acute MI

Sameer Shrivastava
Acute myocardial infarction ( AMI ) is the rapid development of myocardial necrosis caused by a critical imbalance between the oxygen supply and demand of the myocardium. Cardiac Biomarkers are Useful in both the diagnosis of AMI and and estimation of prognosis. Prognostically there is a quantitative relationship between the magnitude of elevation of marker levels and the risk of an adverse event. The Ideal Biomarker should be easy to measure, widely available, inexpensive and high early as well as late AMI sensitivity and high specificity for AMI. Biomarkers currently being used routinely in clinical practice are CK-MB, Troponin and Myoglobin: Diagnostic criteria of Biomarkers for detecting myocardial necrosis include -maximum cTnT or cTnI 99th percentile of reference group on one occasion during 1st 24hours, or maximal CK MB exceeding 99th percentile for reference group on two successive samples or maximal value twice the upper limit of normal, values for CK MB should rise and fall, -CK is not recommended for diagnosis but may or should be continued for scientific or epidemiological purposes, -CK MB or Myoglobin may be needed to detect re-infarction. Creatine Kinase is inexpensive, quick and low, unchanging values, exclude active MI. But it is Non -specific -any muscle can raise the levels. It exceeds normal range whithin 4 to 8 hours after the onset of MI, peak in 10 to 30 hours (avg 24 hours), and usually return to normal in 2 to 3 days . It is fractionated into 3 isoenzymes MM, MB, and BB. The isoenzyme CK-MB has highest concentration in myocardium while neither CK-MM nor CK-BB is clinically relevant for detecting myocardial necrosis. Myoglobin gives early diagnosis (released from the myocardium within 1-4 hours of MI and peak level reached within 6-7 hours) and has Short half-life (Return to normal range within 24 hours). The major disadvantage is lack of cardiac specificity. Isoenzme 1 of LDH is clinically relevant in diagnosis of AMI. Levels start to increase 24 to 48 hours after MI. Peak in 3 to 6 days, and returns to normal in 8 to 14 days. B Natriuretic Polypeptide -after a myocardial infarction, a higher plasma level of BNP is associated with a larger infarct size, an increased likelihood of ventricular remodeling, a lower ejection fraction, and an increased risk of heart failure and death Increased BNP at 48 hours post MI is an independent variable for increased mortality Blood assay available now can be run in 20 -30 minutes.
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, and whose epitope is localized on the proBNP 1-108 cleavage site, present only in the intact form, was generated. By combining this mAb in capture with an anti-BNP 1-32 mAb in detection, a significantly increased proBNP 1-108 concentration in the CHF patients compared with the healthy individuals was recorded (P < 0.0005). Moreover, this increase paralleled the disease severity, as judged by the NYHA classification. In contrary, proBNP 1-108 levels are independent of age, body mass index, gender and renal function. By investigating the relationship of proBNP 1-108 with its cleavage products, we obtained that proBNP 1-108 presents a significant linear relationship with BNP 1-32 and a non-linear relationship with NT-proBNP 1-76 in patients with CHF. Consequently, proBNP 1-108 has a potential clinical interest to diagnose CHF.
Curriculum Vitae:
Villard -Saussine Sylvie has done Ph.D. He is currently R&D Project Leader in Cardiology field in BioRad Laboratorys, France. His areas of interest include immunology, cardiology, diagnostics and hemostasis. He has 19 research papers published in international journals. Coronary artery disease is highly prevalent in the Indian subcontinent and has the highest rate as compared to the western population. Both environmental and genetic factors contribute to the development of CAD. Several population groups have been screened for single nucleotide polymorphisms (SNP's) occuring in various genes, targeting both the atherosclerotic and the thrombotic aspect of CAD. We took into account the various risk factors that play a role in CAD and targeted the genes that participate in the lipid and lipoprotein metabolism, renin angiotensin system, homocysteine, and thrombotic aspect. Genomic profiling will help us in the treatment of coronary risk prone patients.
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